A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.

被引：4
|
作者：
Ullenhag, Gustav J.
Yachnin, Jeffrey
Carneiro, Ana
Elison, Emma
Carlsson, Malin
Russell, Charlotte Astrid
Smith, Karin Enell
机构：
[1] Akad Sjukhus, Uppsala, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Lund Univ Hosp, Lund, Sweden
[4] Lund Univ, Lund, Sweden
[5] Alligator Biosci, Lund, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2646
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2646
引用
收藏
页数：2
相关论文
共 50 条
  • [1] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
    Carneiro, Ana
    Hahn, Amanda
    Ellmark, Peter
    Enell Smith, Karin
    Schultz, Lena
    Ambarkhane, Sumeet
    Yachnin, Jeffrey
    Ullenhag, Gustav J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
  • [2] Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
    Ullenhag, Gustav J.
    Carneiro, Ana
    Smith, Karin Enell
    Schultz, Lena
    Ambarkhane, Sumeet Vijay
    Landstrom, Tova
    Yachnin, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] ATOR-1017, A 4-1BB ANTIBODY, DEMONSTRATES PROMISING SAFETY AND PROOF OF MECHANISM IN A FIRST-IN-HUMAN STUDY IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
    Carneiro, Ana
    Ambarkhane, Sumeet
    Smith, Karin Enel
    Ullenhag, Gustav
    Schulz, Lena
    Landstrom, Tova
    Ellmark, Peter
    Carlsson, Malin
    Yachnin, Jeffrey
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A747 - A747
  • [4] ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer
    Werchau, Doreen
    Rosen, Anna
    Eriksson, Mia
    Jarnum, Sofia
    Furebring, Christina
    Smith, Karin Enell
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [5] ATOR-1017: A 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy
    Dahlen, Eva
    Rosen, Anna
    Barchan, Karin
    Dahlman, Anna
    Ellmark, Peter
    Furebring, Tina
    Smith, Karin Enell
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [6] ATOR-1017, A SECOND GENERATION 4-1BB ANTIBODY WITH POTENTIAL TO ENHANCE EFFICACY OF PD-1 THERAPIES
    Smith, Karin Enell
    Nilsson, Anneli
    Ellmark, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A595 - A595
  • [7] A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies.
    Infante, Jeffrey R.
    Goel, Sanjay
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Robbins, Paul B.
    D'Angelo, Gina
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [9] A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.
    Yachnin, Jeffrey
    Ullenhag, Gustav J.
    Carneiro, Ana
    Nielsen, Dorte
    Rohrberg, Kristoffer Staal
    Kvarnhammar, Anne Mansson
    Dahlman, Anna
    Bageman, Erika
    Wennersten, Camilla
    Russell, Charlotte Astrid
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors
    Ahnert, Jordi Rodon
    Spigel, David R.
    Kremer, Jill
    Jin, Leah
    Benhadji, Karim Adnane
    Gil, Maciej
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345